We all know that imaging data is growing at an unprecedented pace with AI accelerating the curve. For healthcare organizations, this means more pressures on storage, infrastructure, performance and long-term planning. Our panel of imaging leaders will introduce a new model that rethinks how imaging data is stored and accessed, with the goal of supporting both innovation and cost predictability. 

We all know that imaging data is growing at an unprecedented pace with AI accelerating the curve. For healthcare organizations, this means more pressures on storage, infrastructure, performance and long-term planning. Our panel of imaging leaders will introduce a new model that rethinks how imaging data is stored and accessed, with the goal of supporting both innovation and cost predictability. 

When UCSF Health’s enterprise imaging team needed to bring two new Dignity Health hospitals into their network, a new data migration project was born. Even after many migrations over many years, there are always new ways to innovate, so say Director of Enterprise Imaging Neil Singh and Enterprise Imaging Architect Roman Bitner-Glindzicz.

Listen in now to this webinar that explores the MEDRAD® Centargo CT Injection System, Bayer’s multi-patient injector designed to enhance workflow efficiency in high-throughput CT suites.

Join us for an engaging peer discussion on in-house 3D post-processing. Discover how top programs nationwide are evolving their labs and leveraging advanced visualization software, AI, and automation to enhance efficiency for both physicians and technologists.

Listen in as a general cardiologist, surgeon, and interventionalist delve into the latest evidence—including the Evolut™ TAVR 5-Year Low Risk data and SMART Trial 2-Year update—to guide appropriate treatment decisions for patients with severe symptomatic aortic stenosis.

Duke University Health System has integrated Barostim into its comprehensive heart failure program. For patients with heart failure with reduced ejection fraction (HFrEF), Barostim is a device therapy that works with drug therapies to target the neurohormonal pathways responsible for heart failure progression and symptoms. Listen in as an advanced heart failure specialist discusses patient selection and post-implant management, the implant procedure, patient care pathways, and how Duke has incorporated Barostim into their system. 

The late-breaking five-year results of the Evolut Low-Risk Trial presented at ACC.25 showed positive results for the Evolut TAVR system when compared to SAVR.